Literature DB >> 9777517

Antibiotic resistance among clinically important gram-positive bacteria in the UK.

A P Johnson1.   

Abstract

The resistance of bacteria to antibiotics, particularly those used for first-line therapy, is an increasing cause for concern. In the UK, the prevalence of resistance to methicillin and mupirocin in Staphylococcus aureus, and to penicillin and macrolides in Streptococcus pneumoniae, appear to be increasing. There has also been an increase in the number of hospitals where glycopeptide-resistant enterococci are known to have been isolated. The increases in methicillin-resistant S. aureus and glycopeptide-resistant enterococci are due, in part, to the inter-hospital spread of epidemic strains. Although new quinolones and streptogramins with activity against Gram-positive bacteria (including strains resistant to currently available agents) are under development, there is no reason to believe that resistance to these agents will not emerge. The control of resistance in Gram-positive bacteria will require a multi-faceted approach, including continued and improved surveillance, a reduction in the unnecessary use of antibiotics, and the application of other strategies such as vaccination.

Entities:  

Mesh:

Year:  1998        PMID: 9777517     DOI: 10.1016/s0195-6701(98)90020-2

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  11 in total

1.  Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.

Authors:  V J Heaton; C E Goldsmith; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

3.  Antimicrobial resistance problems in a university hospital.

Authors:  Uchenna Chinedu Ozumba
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

4.  Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the Department of Health.

Authors: 
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

5.  Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis.

Authors:  M H Reacher; A Shah; D M Livermore; M C Wale; C Graham; A P Johnson; H Heine; M A Monnickendam; K F Barker; D James; R C George
Journal:  BMJ       Date:  2000-01-22

6.  Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

Authors:  T Lu; X Zhao; X Li; A Drlica-Wagner; J Y Wang; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci.

Authors:  Alan P Johnson; Marina Warner; Michael Carter; David M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Surveillance of nosocomial infections at a Saudi Arabian military hospital for a one-year period.

Authors:  Moataz M Abdel-Fattah
Journal:  Ger Med Sci       Date:  2005-09-01

Review 9.  Quinolones: action and resistance updated.

Authors:  Karl Drlica; Hiroshi Hiasa; Robert Kerns; Muhammad Malik; Arkady Mustaev; Xilin Zhao
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  Bactericidal activities of GM flax seedcake extract on pathogenic bacteria clinical strains.

Authors:  Magdalena Zuk; Agata Dorotkiewicz-Jach; Zuzanna Drulis-Kawa; Malgorzata Arendt; Anna Kulma; Jan Szopa
Journal:  BMC Biotechnol       Date:  2014-07-29       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.